Capecitabine maintenance therapy in metastatic colorectal cancer patients with no evidence of disease : CAMCO trial
Background: In patients with metastatic colorectal cancer (mCRC) exhibiting no evidence of disease (NED), this study assessed the efficacy and safety of capecitabine maintenance therapy. Methods: The single-arm, phase II CAMCO trial enrolled mCRC-NED patients after first-line treatment, administering oral capecitabine maintenance for 1 year. Results: A total of 93 patients were enrolled. The primary end point, 3-year disease-free survival, yielded a rate of 51.6% (95% CI: 41.3-62.0%). Secondary end points included a 3-year overall survival rate of 83.9% (95% CI: 76.3-91.5%). Grade 3 adverse events (AE) were observed in seven patients (7.5%). Predominantly grade 1 and 2, the most common AE was hand-foot syndrome. Conclusion: In mCRC-NED patients, capecitabine maintenance demonstrated a manageable 3-year disease-free survival rate of 51.6%, accompanied by manageable AEs. Clinical Trial Registration: NCT01880658 (ClinicalTrials.gov).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Future oncology (London, England) - 19(2023), 30 vom: 30. Sept., Seite 2045-2054 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ling, Jiayu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
6804DJ8Z9U |
|---|
| Anmerkungen: |
Date Completed 27.10.2023 Date Revised 27.10.2023 published: Print-Electronic ClinicalTrials.gov: NCT01880658 Citation Status MEDLINE |
|---|
| doi: |
10.2217/fon-2023-0149 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363079874 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363079874 | ||
| 003 | DE-627 | ||
| 005 | 20231226092604.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/fon-2023-0149 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1210.xml |
| 035 | |a (DE-627)NLM363079874 | ||
| 035 | |a (NLM)37814832 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ling, Jiayu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Capecitabine maintenance therapy in metastatic colorectal cancer patients with no evidence of disease |b CAMCO trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.10.2023 | ||
| 500 | |a Date Revised 27.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT01880658 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: In patients with metastatic colorectal cancer (mCRC) exhibiting no evidence of disease (NED), this study assessed the efficacy and safety of capecitabine maintenance therapy. Methods: The single-arm, phase II CAMCO trial enrolled mCRC-NED patients after first-line treatment, administering oral capecitabine maintenance for 1 year. Results: A total of 93 patients were enrolled. The primary end point, 3-year disease-free survival, yielded a rate of 51.6% (95% CI: 41.3-62.0%). Secondary end points included a 3-year overall survival rate of 83.9% (95% CI: 76.3-91.5%). Grade 3 adverse events (AE) were observed in seven patients (7.5%). Predominantly grade 1 and 2, the most common AE was hand-foot syndrome. Conclusion: In mCRC-NED patients, capecitabine maintenance demonstrated a manageable 3-year disease-free survival rate of 51.6%, accompanied by manageable AEs. Clinical Trial Registration: NCT01880658 (ClinicalTrials.gov) | ||
| 650 | 4 | |a Clinical Trial, Phase II | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a capecitabine maintenance therapy | |
| 650 | 4 | |a disease-free survival | |
| 650 | 4 | |a hand-foot syndrome | |
| 650 | 4 | |a mCRC-NED patients | |
| 650 | 4 | |a overall survival | |
| 650 | 4 | |a single-arm phase II trial | |
| 650 | 7 | |a Capecitabine |2 NLM | |
| 650 | 7 | |a 6804DJ8Z9U |2 NLM | |
| 700 | 1 | |a Lin, Ziqin |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Lishuo |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yan |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xin |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Junyan |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jianxia |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Jianwei |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Huabin |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, Yue |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Yanhong |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Future oncology (London, England) |d 2005 |g 19(2023), 30 vom: 30. Sept., Seite 2045-2054 |w (DE-627)NLM161450725 |x 1744-8301 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2023 |g number:30 |g day:30 |g month:09 |g pages:2045-2054 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/fon-2023-0149 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2023 |e 30 |b 30 |c 09 |h 2045-2054 | ||